HealthValue
MULTIPLE SCLEROSIS : new drugs
S1P agonists :
fingolimod (inhibits ceramide-synthases, like the poisonous Mycotoxin Fumonisin)
BAF-312
ONO-4641
DNA interference :
teriflunomide (inhibits de novo pyrimidine synthesis for DNA replication, such as necessary for lymphocyte response to auto-antigens) but preserves DNA replication for cells living on their pyrimidine pool: the so called salvage pathway)
cladribine
K channel blockers :
fampridine
Beta interferons :

Anti-integrins :
natalizumab
firategrast
CDP-323
ATL1102
B cell inhibitors :
rituximab anti CD 20 (only directly affects B lymphocytes)
ocrelizumab
alemtuzumab (anti CD 52, affects T and B lymphocytes, as well as dendritic cells)
ofatumumab
GA-101
R7159
Anti CD 25 :
daclizumab
Immunomodulators :
glatiramer
laquinimod
Remyelinating agents :
Lingo antagonists
PI-2301
BHT-3009
dimethylfumarate (BG12) activates nuclear factor (erythroid-derived 2)-related factor 2, hence improving^reservation of myelin